Clinical Research Directory
Browse clinical research sites, groups, and studies.
Sustainable and Efficient Platform Trial of New Therapeutic Development for Early Breast Cancer
Sponsor: Nagoya City University
Summary
Randomized phase II trial targeting early-stage breast cancer (stage II-III) applicable to preoperative chemotherapy (NAC), comparing standard treatment with multiple experimental treatments.
Official title: Sustainable and Efficient Platform of New Therapeutic Development for Early Breast Cancer (S-FACT)
Key Details
Gender
All
Age Range
18 Years - 80 Years
Study Type
INTERVENTIONAL
Enrollment
100
Start Date
2024-07-30
Completion Date
2040-06-30
Last Updated
2025-11-20
Healthy Volunteers
No
Conditions
Interventions
TN
Carboplatin + paclitaxel + pembrolizumab followed by doxorubicin + cyclophosphamide + pembrolizumab
TN-1
Carboplatin + paclitaxel + pembrolizumab followed by niraparib + pembrolizumab Niraparib Pembrolizumab AC
Locations (1)
Nagoya City University
Nagoya, Aichi-ken, Japan